These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3299683)

  • 1. Postmarketing experience with auranofin in the Federal Republic of Germany.
    Schattenkirchner M; Missler B; Mulz D
    Scand J Rheumatol Suppl; 1986; 63():57-66. PubMed ID: 3299683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of auranofin: a review of clinical experience.
    Blodgett RC; Pietrusko RG
    Scand J Rheumatol Suppl; 1986; 63():67-78. PubMed ID: 3110943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Auranofin: first choice for remission-inducing drug (RID) therapy in rheumatoid arthritis?
    Bandilla K; Missler B; Klein-Reesink B
    Scand J Rheumatol Suppl; 1986; 63():47-54. PubMed ID: 3474777
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of auranofin as demonstrated by improvement in clinical parameters and decrease in anti-inflammatory usage: a long-term, multicenter study.
    Brenol JC; Chahade W; De Freitas GG; De Pádua PM; Rachid A; Samara A; Seda H; Ximenes AC
    Scand J Rheumatol Suppl; 1986; 63():37-45. PubMed ID: 3299682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open study on the efficacy and safety of auranofin in treating psoriatic arthritis.
    Dequeker J; Gevers G
    Scand J Rheumatol Suppl; 1986; 63():85-95. PubMed ID: 3474779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An analysis of worldwide safety experience with auranofin.
    Heuer MA; Pietrusko RG; Morris RW; Scheffler BJ
    J Rheumatol; 1985 Aug; 12(4):695-9. PubMed ID: 3932651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prospective clinical study of the combination therapy of auranofin and methotrexate for rheumatoid arthritis--a multi-center study].
    Kashiwazaki S; Akizuki M; Ichikawa Y; Uchida S; Kondo H; Torikai K; Hayashi T; Hara M; Matsuoka Y
    Ryumachi; 1996 Jun; 36(3):528-44. PubMed ID: 8779790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy and safety of auranofin compared to placebo in rheumatoid arthritis.
    Katz WA; Alexander S; Bland JH; Blechman W; Bluhm GB; Bonebrake RA; Falbo A; Greenwald RA; Hartman S; Hobbs T; Indenbaum S; Lergier JE; Lanier BG; Lightfoot RW; Phelps P; Sheon RP; Torretti D; Wenger ME; Wilske K
    J Rheumatol Suppl; 1982; 8():173-8. PubMed ID: 6813481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gold therapy in rheumatoid arthritis. Interim report of the Canadian multicenter prospective trial comparing sodium aurothiomalate and auranofin.
    Menard HA; Beaudet F; Davis P; Harth M; Percy JS; Russell AS; Thompson JM
    J Rheumatol Suppl; 1982; 8():179-83. PubMed ID: 6813482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Auranofin therapy in juvenile rheumatoid arthritis: a 48-week phase II study.
    Kvien TK; Høyeraal HM; Sandstad B; Kass E
    Scand J Rheumatol Suppl; 1986; 63():79-83. PubMed ID: 3474778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Well controlled comparative study in early rheumatoid arthritis with gold sodium thiomalate vs. auranofin].
    Yamamoto S; Mitomo N; Saito T; Nishioka K; Inoue K; Uchida S; Ohata N; Murasawa A; Suzuki A; Mitsui T
    Ryumachi; 1990 Feb; 30(1):26-44. PubMed ID: 2116042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical effectiveness and tolerance of auranofin in patients with chronic polyarthritis. Results of a multicenter long-term study].
    Klein G; Schwann H; Mirtl B; Thumb N; Mayerhofer F; Singer F; Tausch G; Gaismayer K; Rieder H; Hartweger A
    Z Rheumatol; 1988; 47(5):342-6. PubMed ID: 3149087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence and management of diarrhea during longterm auranofin therapy.
    Wallin BA; McCafferty JP; Fox MJ; Cooper DR; Goldschmidt MS
    J Rheumatol; 1988 Dec; 15(12):1755-8. PubMed ID: 3265956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Auranofin improves outcome in early rheumatoid arthritis. Results from a 2-year, double blind placebo controlled study.
    Borg G; Allander E; Lund B; Berg E; Brodin U; Pettersson H; Trang L
    J Rheumatol; 1988 Dec; 15(12):1747-54. PubMed ID: 14552308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis.
    Champion GD; Cairns DR; Bieri D; Adena MA; Browne CD; Cohen ML; Day RO; Edmonds JP; Graham GG; de Jager J
    J Rheumatol; 1988 Jan; 15(1):28-34. PubMed ID: 3280795
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
    Farahani P; Levine M; Gaebel K; Thabane L
    Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis. A double-blind, comparative multicenter study.
    Schattenkirchner M; Kaik B; Muller-Fassbender H; Rau R; Zeidler H
    J Rheumatol Suppl; 1982; 8():184-9. PubMed ID: 6813483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Auranofin.
    Davis P
    Clin Rheum Dis; 1984 Aug; 10(2):369-83. PubMed ID: 6239742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
    Lode H; Vogel F; Elies W
    Clin Ther; 1999 Jan; 21(1):61-74; discussion 1-2. PubMed ID: 10090425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A double-blind study comparing sodium aurothiomalate and auranofin in patients with rheumatoid arthritis previously stabilized on sodium aurothiomalate.
    Hull RG; Morgan SH; Parke AL; Childs L; Goldman M; Hughes GR
    Int J Clin Pharmacol Res; 1984; 4(6):395-401. PubMed ID: 6442711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.